Protocols: Editas adds CRISPR/Cas9 IP; biosimilars make fresh gains in U.S. market
Editas $EDIT has picked up some fresh CRISPR/Cas9 IP from Mass General. The gene editing pioneer, which has focused on adding fresh tech in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
